Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007

Obstetrics and Gynecology

Volumn 121, Issue 1, 2013, Pages 106-114

  Lawrence, Jean M ^a   Andrade, Susan E ^b   Avalos, Lyndsay A ^b   Beaton, Sarah J ^b   Chiu, Vicki Y ^b   Davis, Robert L ^b   Dublin, Sascha ^b   Pawloski, Pamala A ^b   Raebel, Marsha A ^b   Smith, David H ^b   Toh, Sengwee ^b   Wang, Jean Q ^b   Kaplan, Sigal ^b   Amini, Thushi ^b   Hampp, Christian ^b   Hammad, Tarek A ^b   Scott, Pamela E ^b   Cheetham, T Craig ^b  

^a KAISER PERMANENTE   (United States)

^b not available

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA; THIAZOLIDENEDIONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; DELIVERY; DIABETES MELLITUS; FEMALE; FEMALE INFERTILITY; HEALTH MAINTENANCE ORGANIZATION; HIGH RISK PREGNANCY; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVE BIRTH; OVARY POLYCYSTIC DISEASE; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; TREND STUDY; UNITED STATES;

EID: 84872101387     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318278ce86     Document Type: Article

References (31)

1. Parisi MA, Spong CY, Zajicek A, Guttmacher AE. We don't know what we don't study: the case for research on medication effects in pregnancy. Am J Med Genet C Semin Med Genet 2011;157:247-50.
2. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
3. Platt MJ, Stanisstreet M, Casson IF, Howard CV, Walkinshaw S, Pennycook S, et al. St Vincent's declaration 10 years on: outcomes of diabetic pregnancies. Diabetic Med 2002;19:216-20.
4. Balsells M, García-Patterson A, Gich I, Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab 2009;94:4284-91.
5. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care 2007;30:S141-6.
6. Ferrara A, Kahn HS, Quesenberry CP, Riley C, Hedderson MM. An increase in the incidence of gestational diabetes mellitus: Northern California, 1991-2000. Obstet Gynecol 2004;103:526-33.
7. Dabelea D, Snell-Bergeon JK, Hartsfield CL, Bischoff KJ, Hamman RF, McDuffie RS. Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program. Diabetes Care 2005;28:579-84.
8. Getahun D, Nath C, Ananth CV, Chavez MR, Smulian JC. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol 2008;198:525.
9. Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008;31:899-904.
10. Feig DS, Razzaq A, Sykora K, Hux JE, Anderson GM. Trends in deliveries, prenatal care, and obstetrical complications in women with pregestational diabetes: a population-based study in Ontario, Canada, 1996-2001. Diabetes Care 2006;29:232-5.
11. Albrecht SS, Kuklina EV, Bansil P, Jamieson DJ, Whiteman MK, Kourtis AP, et al. Diabetes trends among delivery hospitalizations in the U.S., 1994-2004. Diabetes Care 2010;33:768-73.
12. Hayes DK, Fan AZ, Smith RA, Bombard JM. Trends in selected chronic conditions and behavioral risk factors among women of reproductive age, behavioral risk factor surveillance system, 2001-2009. Prev Chronic Dis 2011;8:A120.
13. Andrade SE, Davis RL, Cheetham TC, Cooper WO, Li DK, Amini T, et al. Medication exposure in pregnancy risk evaluation program. Matern Child Health J 2012;16:1349-54.
14. Andrade SE, Scott PE, Davis RL, Li DK, Getahun D, Cheetham TC, et al. Validity of health plan and birth certificate data for pregnancy research. Pharmacoepidemiol Drug Saf 2012 Jul. doi: 10.1002/pds.3319 [Epub ahead of print].
15. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews TJ, Kirmeyer S, et al. Births: final data for 2007. Natl Vital Stat Rep 2010;58:1-85.
16. Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf 2005;14:829-36.
17. Toh S, Mitchell AA, Werler MM, Hernandez-Diaz S. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008;167:633-40.
18. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327: 951-3.
19. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. The Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.:CD003053. DOI: 10.1002/14651858.CD003053.
20. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit 2006;28:67-72.
21. Gutzin SJ, Kozer E, Magee LA, Feig DS, Koren G. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis. Can J Clin Pharmacol 2003;10:179-83.
22. Gilbert C, Valois M, Koren G. Pregnancy outcome after firsttrimester exposure to metformin: a meta-analysis. Fertil Steril 2006;86:658-63.
23. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003-15.
24. Lawrence JM, Hsu J-W, Chen W, Black MH, Sacks DA. Prevalence and timing of postpartum glucose testing and sustained glucose dysregulation after gestational diabetes mellitus. Diabetes Care 2010;33:569-76.
25. Ferrara A, Peng T, Kim C. Trends in postpartum diabetes screening and subsequent diabetes and impaired fasting glucose among women with histories of gestational diabetes mellitus: a report from the Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care. 2009;32:269-74.
26. Andrade SE, Moore Simas TA, Boudreau D, Raebel MA, Toh S, Syat B, et al. Validation of algorithms to ascertain clinical conditions and medical procedures used during pregnancy. Pharmacoepidemiol Drug Saf 2011;20:1168-76.
27. Dabelea D, Bell RA, D'Agostino RB Jr, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. JAMA 2007;297:2716-24.
28. Liese AD, D'Agostino RB Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006;118:1510-8.
29. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and preg- nancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33: 676-82.
30. Black MH, Sacks DA, Xiang AH, Lawrence JM. Clinical outcomes of pregnancies complicated by mild gestational diabetes mellitus differ by combinations of abnormal oral glucose tolerance test values. Diabetes Care 2010;33: 2524-30.
31. Holt RI, Coleman MA, McCance DR. The implications of the new International Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criteria for gestational diabetes. Diabetic Med 2011;28:382-5.